RxDoctor Payments Data

Showkat Haji, MD

Interventional Cardiology · Memphis, TNNPI 1801099775

Payments from drug & device makers

$1,506in general payments, 2019–2025

Across 68 payments — averaging $22.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$260
  • Medtronic$181
  • Boston Scientific$159
  • Abiomed$145
  • Pfizer$141
  • Baxter Healthcare$135
  • plus $485 from 11 others

What the payments were for

  • Food & beverage$1,506100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,506 in reported general payments places this provider in the 10th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$67,710
Medicare patients
744
Services billed
1,523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$28,917
EntrestoSacubitril/Valsartan23$22,662
JardianceEmpagliflozin12$21,798
FarxigaDapagliflozin Propanediol11$14,483
Carvedilol107$886
Metoprolol Succinate66$624
Atorvastatin Calcium28$343
Isosorbide Mononitrate ErIsosorbide Mononitrate23$295
Amlodipine Besylate56$294
Lisinopril38$239
Furosemide19$178
ClopidogrelClopidogrel Bisulfate26$167
Metoprolol Tartrate19$161
Losartan Potassium20$150
Spironolactone19$126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$141$28,91722 claims
AstraZenecaFarxiga$63$14,48311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 207 interventional cardiology providers in Tennessee.

Other interventional cardiology in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →